IRLAB Therapeutics
IRLAB | ST
Overview
Corporate Details
- ISIN(s):
- SE0012675361 (+1 more)
- LEI:
- 549300JAT34LHEI0DH60
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://irlab.se/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease. We have a well-defined, strategically focused R&D pipeline of powerful new treatments targeting the various stages of Parkinson’s as they worsen over time throughout the patient’s journey of neurodegeneration. Having a full range of effective disease management options for Parkinson’s patients is regarded as essential by both the medical and patient communities – and at the same time potentially a blockbuster pharmaceutical business.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for IRLAB Therapeutics.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-11 09:00 |
Board/Management Information
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
|
English | 39.6 KB | |
| 2025-08-11 09:00 |
Board/Management Information
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
|
Swedish | 40.0 KB | |
| 2025-07-18 18:31 |
Share Issue/Capital Change
IRLAB announces the outcome of the company’s rights issue
|
English | 64.4 KB | |
| 2025-07-18 18:31 |
Share Issue/Capital Change
IRLAB offentliggör utfall i bolagets företrädesemission
|
Swedish | 64.4 KB | |
| 2025-07-14 07:00 |
Share Issue/Capital Change
Sista dag för handel med teckningsrätter i IRLAB:s företrädesemission
|
Swedish | 55.9 KB | |
| 2025-07-14 07:00 |
Share Issue/Capital Change
Last day of trading in subscription rights in IRLAB’s rights issue
|
English | 56.0 KB | |
| 2025-07-03 07:00 |
Share Issue/Capital Change
The subscription period in IRLABS’s rights issue of shares commence today
|
English | 57.2 KB | |
| 2025-07-03 07:00 |
Share Issue/Capital Change
Idag inleds teckningsperioden i IRLAB:s företrädesemission av aktier
|
Swedish | 57.4 KB | |
| 2025-07-02 15:00 |
Prospectus
IRLAB offentliggör informationsdokument i samband med företrädesemissionen
|
Swedish | 56.0 KB | |
| 2025-07-02 15:00 |
Share Issue/Capital Change
IRLAB publishes information document in connection with the rights issue
|
English | 56.0 KB | |
| 2025-06-24 07:57 |
Share Issue/Capital Change
The Board of Directors of IRLAB has resolved on an 85 per cent secured rights i…
|
English | 75.6 KB | |
| 2025-06-24 07:57 |
Share Issue/Capital Change
IRLAB genomför en till 85 procent garanterad företrädesemission om cirka 136 MS…
|
Swedish | 75.2 KB | |
| 2025-06-11 18:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämman 2025 i IRLAB Therapeutics AB
|
Swedish | 45.8 KB | |
| 2025-06-11 18:30 |
Post-Annual General Meeting Information
Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB
|
English | 44.5 KB | |
| 2025-05-12 08:30 |
Pre-Annual General Meeting Information
KALLELSE TILL ÅRSSTÄMMA I IRLAB THERAPEUTICS AB
|
Swedish | 65.6 KB |
Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-05 | Kristina Torfgård | Other | Buy | 9,000 | 140,850.00 SEK |
| 2024-08-05 | Kristina Torfgård | Other | Buy | 4,500 | 70,875.00 SEK |
| 2024-05-14 | Gunnar Olof Olsson | Other | Buy | 2,000 | 31,000.00 SEK |
| 2024-05-10 | Daniel Johnsson | Other | Buy | 20,000 | 259,680.00 SEK |
| 2023-04-03 | Joakim Tedroff | Other | Buy | 51,430 | 2,038,685.20 SEK |
| 2022-09-01 | Richard Godfrey | Other | Buy | 5,000 | 174,457.00 SEK |
| 2022-08-30 | Viktor Siewertz | Other | Buy | 40 | 1,420.00 SEK |
| 2022-08-29 | Viktor Siewertz | Other | Sell | 40 | 1,408.00 SEK |
| 2022-07-15 | Joakim Tedroff | Other | Other | 84,148 | N/A |
| 2022-05-31 | Viktor Siewertz | Other | Buy | 4,500 | 170,370.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
CHOSA Oncology AB | Sweden | CHOSA | |
|
Cinclus Pharma Holding AB | Sweden | CINPHA | |
|
Circio Holding ASA | Norway | CRNA | |
|
CIZZLE BIOTECHNOLOGY HOLDINGS PLC | United Kingdom | CIZ | |
|
CLAL Biotechnology Industries Ltd. | Israel | CBI | |
|
Combigene AB | Sweden | COMBI | |
|
Compugen Ltd. | Israel | CGEN | |
|
Corline Biomedical AB | Sweden | CLBIO | |
| CRISM Therapeutics Corporation | Virgin Islands (British) | N/A | ||
|
Curasight A/S | Denmark | CURAS |